San Juan, Calif.-based SI-BONE released the safety data for the first 5,319 patients treated with the company's iFuse Implant System for degenerative sacroiliitis and sacroiliac joint disruption.
The study, published in Medical Devices: Evidence and Research, studied procedures in the United Kingdom and Canada from April 2009 to January 2013. The overall post-market complaint rate was 3.8 percent, with a total revision rate of 1.8 percent and a late postoperative revision rate of 0.6 percent.
More Articles on Devices:
TranS1 Completes Acquisition of Baxano Spine Device Manufacturer
RTI Biologics Donates 35 Bone Allograft Implants to Kenyan Children's Hospital
14 News Updates for Spine & Orthopedic Device Companies
More Articles on Devices:
TranS1 Completes Acquisition of Baxano Spine Device Manufacturer
RTI Biologics Donates 35 Bone Allograft Implants to Kenyan Children's Hospital
14 News Updates for Spine & Orthopedic Device Companies